Freenome与罗氏达成独家协议 拓展技术合作以开发和商业化美国以外的癌症筛查测试

投资观察
Nov 18

罗氏控股有限公司:*FREENOME:宣布与罗氏达成独家协议,以扩大技术合作,开发和商业化美国以外的癌症筛查测试。*FREENOME:保留美国以外集中测试的权利,以及所有美国的权利,但须遵循与精密科学(Exact Sciences)之前的许可协议。*FREENOME:价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) 来源日期/时间 = 2025-11-18 14:00:06.74 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10